Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander C Schmidt

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
The Lancet. HIV|July 4, 2025
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01<sub>E-4</sub> in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trialAlemnew F Dagnew, Linda L Han, Kogieleum Naidoo, et al.
Virology|July 30, 2010
Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primatesAnne Schaap-Nutt, Christopher D'Angelo, Emerito Amaro-Carambot, et al.
The New England Journal of Medicine|May 7, 2025
BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> InfectionAlexander C Schmidt, Lee Fairlie, Elizabeth Hellström, et al.
The American Journal of Tropical Medicine and Hygiene|July 19, 2017
Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United StatesAlexander C Schmidt, Leyi Lin, Luis J Martinez, et al.
Vaccine|October 10, 2013
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young childrenJanet A Englund, Ruth A Karron, Coleen K Cunningham, et al.
The American Journal of Tropical Medicine and Hygiene|March 4, 2020
Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I StudyClemente Diaz, Michael Koren, Leyi Lin, et al.
Vaccine Insights|April 24, 2023
The quest for vaccine-induced immune correlates of protection against tuberculosisElisa Nemes, Andrew Fiore-Gartland, Cesar Boggiano, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
End-point definition and trial design to advance tuberculosis vaccine developmentAlberto L Garcia-Basteiro, Richard G White, Dereck Tait, et al.
The Lancet. Microbe|July 4, 2024
Implications of subclinical tuberculosis for vaccine trial design and global effectGavin J Churchyard, Rein M G J Houben, Katherine Fielding, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
The Lancet. HIV|July 4, 2025
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01<sub>E-4</sub> in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trialAlemnew F Dagnew, Linda L Han, Kogieleum Naidoo, et al.
Virology|July 30, 2010
Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primatesAnne Schaap-Nutt, Christopher D'Angelo, Emerito Amaro-Carambot, et al.
The New England Journal of Medicine|May 7, 2025
BCG Revaccination for the Prevention of <i>Mycobacterium tuberculosis</i> InfectionAlexander C Schmidt, Lee Fairlie, Elizabeth Hellström, et al.
The American Journal of Tropical Medicine and Hygiene|July 19, 2017
Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United StatesAlexander C Schmidt, Leyi Lin, Luis J Martinez, et al.
Vaccine|October 10, 2013
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young childrenJanet A Englund, Ruth A Karron, Coleen K Cunningham, et al.
The American Journal of Tropical Medicine and Hygiene|March 4, 2020
Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I StudyClemente Diaz, Michael Koren, Leyi Lin, et al.
Vaccine Insights|April 24, 2023
The quest for vaccine-induced immune correlates of protection against tuberculosisElisa Nemes, Andrew Fiore-Gartland, Cesar Boggiano, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|June 8, 2022
End-point definition and trial design to advance tuberculosis vaccine developmentAlberto L Garcia-Basteiro, Richard G White, Dereck Tait, et al.
The Lancet. Microbe|July 4, 2024
Implications of subclinical tuberculosis for vaccine trial design and global effectGavin J Churchyard, Rein M G J Houben, Katherine Fielding, et al.
Pageof 6